Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

Understanding Prostate Cancer Mutations Is Critical

Tuesday, March 19, 2019

The BRCA1 and BRCA2 genes, which have typically been associated with breast and ovarian cancer, are proving to be important in the prostate cancer space, too, said Leonard G. Gomella, MD, FACS, director of the Kimmel Cancer Center Network and chair of the department of urology at the Sidney Kimmel Cancer Center at Thomas Jefferson University. 

While the genes do not seem to actually cause cancer, patients with prostate cancer who have BRCA mutations tend to have more aggressive disease, making it even more important for providers to better understand the genetic makeup of the disease.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.